Welcome to our dedicated page for Sunshine Biopharma news (Ticker: SBFM), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma stock.
Sunshine Biopharma Inc. reports developments as a pharmaceutical company with commercial generic prescription drugs in Canada and proprietary drug-development programs in oncology and antivirals. News commonly covers product launches through its Nora Pharma subsidiary, including generic medicines such as Domperidone, Doxycycline and Pravastatin, as well as Health Canada commercialization approvals and expansion of therapeutic categories.
The company’s updates also address financial results, portfolio growth and research programs including K1.1 mRNA, an mRNA-lipid nanoparticle candidate targeting liver cancer, and a PLpro protease inhibitor for SARS-related coronavirus infections. Corporate and treasury actions may appear alongside operating updates when they affect Sunshine Biopharma’s capital strategy or public-company profile.
Sunshine Biopharma (OTC PINK:SBFM) has successfully synthesized four potential inhibitors targeting the Coronavirus protease, a crucial component for the virus's replication. This advancement stems from a recently filed patent for small molecules aimed at treating Coronavirus infections, including COVID-19. The next steps involve analyzing the binding affinity of these compounds to the SARS-CoV-2 papain-like protease, selecting a lead candidate for further development. Sunshine is also advancing its anticancer drug, Adva-27a, which has shown effectiveness against multidrug-resistant cancer cells.